Most Recent
Biotech company Cryosite has agreed to pay $1.05 million to settle the competition regulator's landmark case alleging it jumped the gun on a proposed merger agreement with rival Cell Care.
AFT Pharmaceuticals has launched a partial challenge to a court ruling that its Maxigesic ads made a number of misleading claims, including that the drug provides stronger and more effective relief than Reckitt Benckiser's Nuromol.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a "ceiling" of 11 types of pneumococcal bacteria that could be included in a single vaccine.
Claims by Wyeth that its patented Prevnar 13 pneumococcal vaccine was inventive because other pharmaceutical giants had failed in developing similar vaccines are based on "hearsay and speculation," Merck Sharp & Dohme told the court during closing submissions in the high-stakes trial over the world's best-selling vaccine.
The judge overseeing a class action against Ethicon over allegedly faulty pelvic mesh implants has shot down the device maker's bid for a class closure order.
A class action against Ethicon over allegedly faulty pelvic mesh implants wants introduce confidential evidence from prior settlement negotiations as it attempts to shut down the medical device maker's class closure application.
Generic drug maker Sun Pharma has emerged victorious in a lawsuit brought against it by Mylan relating to Sun's plans to launch a generic version of cholesterol drug fenofibrate.
Denmark-based Lundbeck cannot recover damages for the alleged infringement of its Lexapro patent by generic drug companies that it dropped its claims against, a judge has found.
Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.